NRX Pharmaceuticals, Inc. (NRXP)
3.42
-0.25
(-6.81%)
USD |
NASDAQ |
Aug 26, 12:00
NRX Pharmaceuticals Enterprise Value : 132.95M for Aug. 25, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 25, 2026 | 132.95M |
| August 24, 2026 | 123.45M |
| August 21, 2026 | 128.20M |
| August 20, 2026 | 126.04M |
| August 19, 2026 | 118.28M |
| August 18, 2026 | 123.02M |
| August 17, 2026 | 122.59M |
| August 14, 2026 | 115.69M |
| August 13, 2026 | 118.71M |
| August 12, 2026 | 119.57M |
| August 11, 2026 | 121.30M |
| August 10, 2026 | 119.14M |
| August 07, 2026 | 129.06M |
| August 06, 2026 | 107.92M |
| August 05, 2026 | 106.41M |
| August 04, 2026 | 106.19M |
| August 03, 2026 | 114.39M |
| July 31, 2026 | 110.51M |
| July 30, 2026 | 109.21M |
| July 29, 2026 | 113.96M |
| July 28, 2026 | 127.34M |
| July 27, 2026 | 131.22M |
| July 24, 2026 | 136.40M |
| July 23, 2026 | 151.94M |
| July 22, 2026 | 167.91M |
| Date | Value |
|---|---|
| July 21, 2026 | 167.04M |
| July 20, 2026 | 154.96M |
| July 17, 2026 | 158.84M |
| July 16, 2026 | 157.55M |
| July 15, 2026 | 167.04M |
| July 14, 2026 | 161.43M |
| July 13, 2026 | 153.66M |
| July 10, 2026 | 155.39M |
| July 09, 2026 | 151.94M |
| July 08, 2026 | 143.74M |
| July 07, 2026 | 154.10M |
| July 06, 2026 | 144.82M |
| July 02, 2026 | 141.58M |
| July 01, 2026 | 141.15M |
| June 30, 2026 | 151.08M |
| June 29, 2026 | 128.11M |
| June 26, 2026 | 119.07M |
| June 25, 2026 | 113.38M |
| June 24, 2026 | 113.38M |
| June 23, 2026 | 120.07M |
| June 22, 2026 | 124.76M |
| June 18, 2026 | 127.10M |
| June 17, 2026 | 127.44M |
| June 16, 2026 | 127.10M |
| June 15, 2026 | 130.78M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Eli Lilly & Co. | 1.207T |
| Pfizer Inc. | 214.62B |
| Oramed Pharmaceuticals, Inc. | 165.37M |
| Yarrow Bioscience, Inc. | 3.306M |
| ANI Pharmaceuticals, Inc. | 1.972B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -16.52M |
| Revenue (Quarterly) | 1.101M |
| Total Expenses (Quarterly) | 17.62M |
| EPS Diluted (Quarterly) | -0.4388 |
| Gross Profit Margin (Quarterly) | 23.43% |
| Profit Margin (Quarterly) | -1.50K% |
| Earnings Yield | -21.54% |
| Normalized Earnings Yield | -15.53 |